254 related articles for article (PubMed ID: 21447431)
1. Using the TOPS-MODE approach to fit multi-target QSAR models for tyrosine kinases inhibitors.
Marzaro G; Chilin A; Guiotto A; Uriarte E; Brun P; Castagliuolo I; Tonus F; González-Díaz H
Eur J Med Chem; 2011 Jun; 46(6):2185-92. PubMed ID: 21447431
[TBL] [Abstract][Full Text] [Related]
2. Improvement of multivariate image analysis applied to quantitative structure-activity relationship (QSAR) analysis by using wavelet-principal component analysis ranking variable selection and least-squares support vector machine regression: QSAR study of checkpoint kinase WEE1 inhibitors.
Cormanich RA; Goodarzi M; Freitas MP
Chem Biol Drug Des; 2009 Feb; 73(2):244-52. PubMed ID: 19207427
[TBL] [Abstract][Full Text] [Related]
3. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors.
Zeng H; Zhang H
J Mol Graph Model; 2010 Aug; 29(1):54-71. PubMed ID: 20471293
[TBL] [Abstract][Full Text] [Related]
4. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
Verkhivker GM
Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
[TBL] [Abstract][Full Text] [Related]
5. A neural network-based QSAR approach for exploration of diverse multi-tyrosine kinase inhibitors and its comparison with a fragment- based approach.
Ajmani S; Viswanadhan VN
Curr Comput Aided Drug Des; 2013 Dec; 9(4):482-90. PubMed ID: 24138419
[TBL] [Abstract][Full Text] [Related]
6. Docking, 3D-QSAR studies and in silico ADME prediction on c-Src tyrosine kinase inhibitors.
Tintori C; Magnani M; Schenone S; Botta M
Eur J Med Chem; 2009 Mar; 44(3):990-1000. PubMed ID: 18722033
[TBL] [Abstract][Full Text] [Related]
7. Kinase-kernel models: accurate in silico screening of 4 million compounds across the entire human kinome.
Martin E; Mukherjee P
J Chem Inf Model; 2012 Jan; 52(1):156-70. PubMed ID: 22133092
[TBL] [Abstract][Full Text] [Related]
8. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.
Ravindra GK; Achaiah G; Sastry GN
Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839
[TBL] [Abstract][Full Text] [Related]
9. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
Wichapong K; Lindner M; Pianwanit S; Kokpol S; Sippl W
Eur J Med Chem; 2009 Apr; 44(4):1383-95. PubMed ID: 18976834
[TBL] [Abstract][Full Text] [Related]
10. Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity.
Martin E; Mukherjee P; Sullivan D; Jansen J
J Chem Inf Model; 2011 Aug; 51(8):1942-56. PubMed ID: 21667971
[TBL] [Abstract][Full Text] [Related]
11. Theoretical studies of QSAR and molecular design on a novel series of ethynyl-3-quinolinecarbonitriles as SRC inhibitors.
Fang DQ; Wu WJ; Zhang R; Zeng GH; Zheng KC
Chem Biol Drug Des; 2012 Jul; 80(1):134-47. PubMed ID: 22429605
[TBL] [Abstract][Full Text] [Related]
12. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.
Du J; Lei B; Qin J; Liu H; Yao X
J Mol Graph Model; 2009 Jan; 27(5):642-54. PubMed ID: 19081278
[TBL] [Abstract][Full Text] [Related]
13. Molecular modelling studies on d-annulated benzazepinones as VEGF-R2 kinase inhibitors using docking and 3D-QSAR.
Lan P; Sun JR; Chen WN; Sun PH; Chen WM
J Enzyme Inhib Med Chem; 2011 Jun; 26(3):367-77. PubMed ID: 20846090
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
15. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.
Charrier JD; Miller A; Kay DP; Brenchley G; Twin HC; Collier PN; Ramaya S; Keily SB; Durrant SJ; Knegtel RM; Tanner AJ; Brown K; Curnock AP; Jimenez JM
J Med Chem; 2011 Apr; 54(7):2341-50. PubMed ID: 21391610
[TBL] [Abstract][Full Text] [Related]
16. QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors.
Koo KA; Kim ND; Chon YS; Jung MS; Lee BJ; Kim JH; Song WJ
Bioorg Med Chem Lett; 2009 Apr; 19(8):2324-8. PubMed ID: 19282176
[TBL] [Abstract][Full Text] [Related]
17. Structural biology contributions to tyrosine kinase drug discovery.
Cowan-Jacob SW; Möbitz H; Fabbro D
Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
[TBL] [Abstract][Full Text] [Related]
18. Development of novel 3D-QSAR combination approach for screening and optimizing B-Raf inhibitors in silico.
Shih KC; Lin CY; Zhou J; Chi HC; Chen TS; Wang CC; Tseng HW; Tang CY
J Chem Inf Model; 2011 Feb; 51(2):398-407. PubMed ID: 21182293
[TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR and docking studies on pyrazolo[4,3-h]qinazoline-3-carboxamides as cyclin-dependent kinase 2 (CDK2) inhibitors.
Lan P; Chen WN; Xiao GK; Sun PH; Chen WM
Bioorg Med Chem Lett; 2010 Nov; 20(22):6764-72. PubMed ID: 20869873
[TBL] [Abstract][Full Text] [Related]
20. Molecular modeling studies of Rho kinase inhibitors using molecular docking and 3D-QSAR analysis.
Qin J; Lei B; Xi L; Liu H; Yao X
Eur J Med Chem; 2010 Jul; 45(7):2768-76. PubMed ID: 20347188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
